News OEM

New Biomaterials for your immunoassay development & manufacturing

Supporting your Immunoassay Portfolio Expansion

June 19, 2024

downstream purification

 

When developing a new immunoassay, having a deep knowledge of the biomaterial helps to optimize R&D resources. 

And what is more, it helps reduce the risk in later stages of the project, where significant commitments are made and the cost of responding to unexpected events increases exponentially.  

How Werfen can support you 

Our experience in immunoassay development and manufacturing helps us understand the challenges you might face as an immunoassay developer & manufacturer.  

In Werfen, we can support your portfolio expansion by supplying reliable biomaterials that have already been used in different immunoassay technologies. 

Following our strategy to expand and diversify our biomaterials’ portfolio, we have added the following references:

  • AMH Antibody-Like Protein

  • Osteocalcin Monoclonal Antibodies

  • Recombinant Toxoplasma Antigen 

 

Click here to download our updated catalogue

Share Press Release:

LinkedIn twitter facebook
Contact us

Please contact us directly via telephone or with the following form.

Tel. +34 93 860 90 00

DATA PROTECTION POLICY:

Biokit, S.A. and Biokit Research & Development, S.L.U. will process your personal data to respond to your requests for information or support, or to understand your needs and provide you with a better service relying on our legitimate interest to do so. You can find more information about our data privacy practices and how to exercise your rights in our Privacy Policy. You can also contact us at DPO-biokit@werfen.com.